Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Does the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?
Sponsor: Anders Fink-Jensen, MD, DMSci
This PHASE4 trial investigates Clozapine and GLP-1 and is currently ongoing. Anders Fink-Jensen, MD, DMSci leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
8 versions recorded-
Oct 2024 — Present [monthly]
Active Not Recruiting PHASE4
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE4
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
Sep 2022 — Nov 2023 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Anders Fink-Jensen, MD, DMSci
For direct contact, visit the study record on ClinicalTrials.gov .